NCT06850922: An ongoing trial by Genentech, Inc.
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06850922 |
|---|---|
| Title | A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 22, 2022 |
| Completion date | April 30, 2027 |
| Required reporting date | April 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 9, 2026 |
| Days late | None |